Neurogen LLC · Nashua, NH
We develop non-opioid drug therapies that address the root neurological mechanisms of chronic pain — not just the symptoms. Patented technology. Personalized medicine.
The Unmet Need
Over a billion people worldwide suffer from chronic pain. All currently prescribed drugs — from opioids to anticonvulsants — treat symptoms only. The moment treatment stops, pain returns, often more intense than before.
Opioids, the only class of drugs specifically designed for pain, trigger dependence, addiction, and a paradoxical effect known as opioid-induced hyperalgesia — making pain worse over time. The current opioid crisis is a direct consequence of this gap in care.
Despite billions spent on research globally, no truly new class of chronic pain therapy has emerged in decades. Neurogen is changing that.
"Numbing the pain for a while will make it worse when you finally feel it."— J.K. Rowling
Our Approach
Neurogen has identified a recently discovered neurological mechanism that explains the physiology and pathology of chronic pain — including genetic variations that create distinct pain syndromes. This breakthrough enables a logical, systematic approach to drug discovery that was previously impossible.
Our innovative, cutting-edge platform uses patented assay systems for targeted drug development, enabling identification of compounds with long-term, durable action.
Unlike palliative approaches, Neurogen drugs are designed to address the underlying cause of chronic pain — enabling effects that persist without continuous administration.
We've developed a novel system of assays specific to our mechanism, enabling high-fidelity screening and selection of candidates with the right target profile.
Several compounds in our pipeline have been validated by centuries of traditional medicine — present in high concentrations in plants used historically to treat pain.
Our Pipeline
Neurogen's goal is to develop chronic pain drugs with long-term action that do not require continuous dosing and that can partially substitute opioid use — with far fewer risks and side effects.
Some compounds are tailored to address chronic pain syndromes resulting from individual genetic variations, opening the door to truly personalized pain medicine.
Get in TouchPartnership Opportunities
Neurogen represents a rare early-stage opportunity to support the development of an entirely new class of chronic pain therapeutics — addressing a massive global unmet medical need with a differentiated scientific approach.
Early-stage equity investment to advance pre-clinical and IND-enabling studies.
Non-dilutive funding opportunities to support foundational research milestones.
Pharma and biotech collaboration for licensing, co-development, or acquisition.
To discuss investment opportunities, contact us at admin@1neurogen.com
Get in Touch
Reach out to learn more about our science, investment opportunities, or potential collaboration.